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Abstract Introduction
Background—In the United States, liquid-based cytology (LBC) has become 
a common screening method for cervical cancer. However, the extent of LBC 
use, and how it varies by patient and practice characteristics, is unknown.
Objective—This report describes the ordering and provision of Papanicolaou 
(Pap) tests, with a major focus on the extent to which LBC has supplanted 
conventional cytology. The type of Pap test is examined for visits made to 
primary care physicians in 2006-2007 by females aged 15-64.
Methods—Estimates of Pap test cytology use (both LBC and conventional) 
are based on combined data from the 2006-2007 National Ambulatory Medical 
Care Survey (NAMCS), an annual nationally representative survey of visits to 
nonfederal office-based physicians in the United States, as well as on information 
reported by sample physicians in Cervical Cancer Screening Supplements fielded 
as part of NAMCS during the same years.
Results—In 2006-2007, LBC was used in approximately 75% of Pap tests 
for which the type of cytology was known. LBC was less likely to be used for 
Medicare patients than for privately insured patients, although LBC use did not 
vary significantly according to the other patient or practice characteristics 
examined.
Conclusion—The high percentage of LBC use by office-based physicians in 
2006-2007 confirms the widespread use of this screening method among primary 
care providers, as has been reported in the literature.
K e yw o rd s : physician visits • cervical cancer screening
In the United States, liquid-based 
cytology (LBC) has rapidly become a 
common method used in cervical 
cancer screening (1-4). Its popularity 
with both medical professionals and 
insurance companies may be related to 
the ease of microscopic interpretation 
and the potential for performing 
additional medical tests on the same 
sample (2,5,6). This popularity may 
also be attributable to direct marketing 
to physicians, to patients, and to 
laboratories (1). However, limited 
information is available on the extent of 
LBC use and how use varies by patient 
and practice characteristics; previous 
studies (1,3,4) were based on selected 
specialties or were conducted in limited 
geographic areas. This report examines 
the type of cytology test ordered or 
provided at primary care visits to 
office-based physicians made by females 
aged 15-64 in the United States in 
2006-2007.
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Methods
All data were obtained from the 
National Ambulatory Medical Care 
Survey (NAMCS), conducted by the 
Centers for Disease Control and 
Prevention’s (CDC) National Center for 
Health Statistics. NAMCS is a national 
probability sample survey of visits to 
nonfederal office-based physicians 
selected from the master files of the 
American Medical Association and the 
American Osteopathic Association. In 
2006, NAMCS began including a 
separate stratum—community health 
centers (CHCs)—which produced an 
additional sample of up to 250 
clinicians. NAMCS utilizes a multistage 
probability sample design involving 
patient visits within physician practices 
among 112 geographic primary sampling 
units. Sampled physicians were asked to 
complete Patient Record Forms (PRFs) 
for a systematic random sample of up to 
30 office visits occurring during a 
randomly assigned 1-week reporting 
period. For each sampled visit, a sample 
weight is computed that takes into 
account all stages of the survey design 
as well as physician response. The 
2006-2007 unweighted response rate 
was 60.3%, with 65,963 PRFs 
completed (7,8).
This report examines the type of 
cytology—LBC, conventional, or 
unspecified—provided or ordered at 
visits to office-based physicians in 
primary care specialties [general/family 
practice, obstetrics-gynecology (ob-gyn), 
internal medicine, and pediatrics] for 
females aged 15-64 who had a 
Papanicolaou (Pap) test (n = 1,667).
The weighted percentage of cytology 
test visits where type of cytology 
was originally reported as unspecified 
was 19.4%. The percentage of 
PRFs abstracted by a Census field 
representative rather than by someone in 
a physician’s office was higher for visits 
with unspecified type of cytology 
(79.6%) than for visits with known type 
(44.9%). Physician responses to the 
2006 and 2007 Cervical Cancer 
Screening Supplements (CCSS) to 
NAMCS were used to edit the 
unspecified responses. CCSS is 
sponsored by CDC’s Division of Cancer
Prevention and Control to examine 
provider practices regarding cervical 
cancer screening. CCSS is self­
administered in physician offices as part 
of NAMCS, and all physician specialties 
in this study were eligible for CCSS. 
Using this information, 181 of the 365 
visits with unspecified cytology type 
were inferred to equal the type of 
cytology reported to be used by sample 
physicians in CCSS. When physicians in 
CCSS reported using both methods, 
unspecified tests were not changed.
After editing, 10.4% of cytology test 
visits remained unspecified (weighted).
Physician characteristics examined 
included practice size (solo, 2-5 
physicians, 6-10 physicians, or 11 or 
more physicians), physician specialty 
[ob-gyn, general or family practice, or 
other (e.g., internal medicine or 
pediatrics)], practice ownership 
[physician or group practice, health 
maintenance organization (HMO), CHC, 
or other ownership], and location of the 
practice (geographic region and 
metropolitan statistical area status). 
Patient characteristics included age and 
race, expected payment source, reason 
for visit (preventive or not), and whether 
a human papillomavirus (HPV) test was 
ordered or provided at the sample visit.
Bivariate differences in the type of 
cytology test, by selected patient and 
practice characteristics, were examined 
using chi-square tests of association at 
the a  = 0.05 level, with Bonferroni 
adjustments for multiple comparisons.
If chi-square tests were statistically 
significant, a post hoc t-test procedure 
was used to make pairwise comparisons 
of type of cytology used between 
different categories of practice or patient 
characteristics. Significant results from 
the post hoc procedure are reported 
here. Differences in types of cytology 
(controlling for patient and provider 
characteristics) were analyzed in a 
logistic regression model, with LBC 
compared with conventional cytology as 
the dependent variable. All estimates 
were obtained using SUDAAN software 
to account for the complex sample 
design of NAMCS (9).
Results
In 2006-2007, females aged 15-64 
made an estimated 210 million visits to 
primary care physicians annually. 
Cytology screening was performed at 
12.5% (26.2 million) of these visits 
(data not shown). Approximately 67.2% 
of tests used LBC, 22.3% used 
conventional cytology, and 10.4% had 
unspecified type of cytology. The 
percentage of tests using LBC varies 
according to assumptions made about 
the nature of the unspecified tests. If the 
unspecified tests are assumed to use 
conventional cytology, 67.2% of 
cytology tests use LBC; however, if the 
same tests are assumed to use LBC, 
77.7% of all cytology tests use LBC.
If unspecified tests are assumed to be 
missing at random (i.e., if only tests of 
known type are included in the 
denominator), 75.1% of tests use LBC.
NAMCS estimates that assume 
unspecified tests use LBC (81.2% for 
ob-gyns compared with 69.6% for 
family physicians) or are missing at 
random (79.3% for ob-gyn and 65.6% 
for family physicians) are more 
consistent with previous study estimates 
(80%-82% LBC among ob-gyns and 
75% among family physicians) (1,5,6) 
than are estimates assuming that the 
unspecified tests use conventional 
cytology (72.2% for ob-gyns and 58.0% 
for family physicians). In the analysis 
that follows, tests with unspecified 
cytology were assumed to be randomly 
distributed and were therefore deleted.
Among visits with known type of 
cytology, a significant bivariate 
association between type of test and 
physician specialty was found (p  < 0.05) 
(Table 1). Ob-gyns were significantly 
more likely to order LBC (79.3%) than 
other primary care physicians (63.0%- 
65.6%) (p  < 0.05 in both cases). Practice 
ownership was also associated with 
LBC provision (p  < 0.05): CHCs 
ordered fewer LBC tests (51.1%) than 
physician- and group-owned practices 
(77.5%) (p < 0.05). Although the overall 
effect of patient’s primary expected 
payment source was only marginally 
significant (p = 0.06), privately insured 
females were significantly more likely
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to have LBC (77.2%) than females 
enrolled in Medicare (50.0%) (p  < 0.05).
Results of a logistic regression for 
LBC relative to conventional cytology 
are presented in Table 2. Relative to 
visits with conventional cytology tests, 
females enrolled in Medicare [odds ratio 
(OR) = 0.28; 95% confidence interval 
(CI) = 0.12-0.65] had lower odds of 
having LBC tests than females relying 
on private insurance, all else remaining 
constant. Practice ownership, region, 
metropolitan statistical area status, 
patient age, race, HPV test provision, 
and preventive care visits were unrelated 
to LBC use in the model. A logistic 
regression model that included all 
unspecified tests and assumed that they 
were all LBC had virtually identical 
results (data not shown).
Discussion
For six decades, cytology testing 
has been used to detect precancerous or 
early cancerous changes in the 
cervix (6). Although in 2003 the U.S. 
Preventive Services Task Force (10) 
cited insufficient evidence to 
recommend LBC over conventional 
cytology for cervical cancer screening, 
LBC has become the most common 
testing method. In the present nationally 
representative study of outpatient visits 
for 2006-2007, approximately 75% of 
cytology tests were liquid-based 
(assuming missing cytology type was 
missing at random). This finding is 
consistent with LBC’s rapid replacement 
of conventional cytology as the most 
common screening method for cervical 
cancer.
Although significant bivariate 
associations were found between LBC 
use and physician specialty and practice 
ownership, these associations were not 
significant when simultaneously 
controlled for in a multivariate logistic 
regression. These bivariate findings are, 
however, consistent with results from 
provider surveys that show that 
providers who practice in environments 
where resources are scarce, or providers 
managed by a larger organization, may
be more likely to use the less expensive 
conventional Pap (11,12). Although the 
model for the present study found that 
Medicare patients were less likely to 
have LBC relative to conventional 
cytology tests (when controlling for all 
other practice and patient 
characteristics), this finding requires 
further research.
LBC tests are more expensive than 
conventional Pap tests. In 2005, 
Medicare reimbursement was 
approximately $15 for a conventional 
Pap test and $27 for LBC (6). The 
higher cost of LBC screenings has put 
financial pressure on public screening 
programs for underserved females, such 
as the National Breast and Cervical 
Cancer Early Detection Program. 
Because clinics providing services for 
the program had a difficult time 
contracting with providers and 
laboratories that performed conventional 
Pap tests, the program changed its 
reimbursement policy to allow payment 
for a Pap test at the higher Medicare 
rate for LBC, provided the LBC 
screening was only done biennially (6).
The data have certain limitations. 
First, the fact that 10.4% of tests had 
unspecified type of cytology means that 
it is not possible to provide a precise 
national estimate of the percentage of 
cytology visits with LBC compared with 
conventional cytology. Even with this 
limitation, the study confirms the 
widespread use of LBC among 
primary care providers, based on a 
nationally representative sample of 
office visits during 2006-2007. 
Although the ease of conducting HPV 
testing on the remaining LBC sample 
has been cited as an advantage of 
LBC, evidence of comparable 
sensitivity and specificity of LBC 
and conventional cytology suggests 
no advantage of one method over 
the other for detecting cervical 
cancer (13-15). HPV testing can also 
be conducted at lower cost with 
conventional cytology through 
co-collection (12). These findings raise 
questions about the impact of frequent 
use of LBC on health care costs (5).
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among visits with 
known type of 
cytology test Total
Percent distribution of 
cytology test v isits by type2
LBC3 Conventional
All v isits (n  -  1 ,4 8 3 )........................................................................................... 100.0 100 75.1 24.9
Practice size4 ( p  -  0.102)
S o lo ......................................................................................................................... 28.4 100 86.0 *14.0
2 -5  p h ys ic ia n s .................................................................................................... 43.5 100 72.4 27.6
6 -1 0  p h y s ic ia n s ................................................................................................. 21.7 100 71.6 28.4
11 or more p h y s ic ia n s .................................................................................... 6.4 100 56.7 43.3
Physician specialty ( p  -  0.033)
Obstetrics or gyneco logy.................................................................................. 70.8 100 79.3 20.7
General or fam ily p ra c t ic e .............................................................................. 21.1 100 65.6 34.4
O ther p rim a ry....................................................................................................... *8.1 100 63.0 37.0
Practice ownership ( p  -  0.020)
Physician or g roup .............................................................................................. 79.9 100 77.5 22.5
Health maintenance organization ............................................................... *2.5 100 *30.6 69.4
Community health c e n t e r .............................................................................. 3.1 100 51.1 48.9
O ther o w n e rsh ip ................................................................................................. 14.5 100 74.7 *25.3
Geographic region ( p  -  0.144)
N o rth e a s t............................................................................................................. 18.3 100 75.6 24.4
M id w e s t................................................................................................................ 20.2 100 72.7 27.3
S o u th ...................................................................................................................... 41.9 100 81.6 18.4
W e s t ...................................................................................................................... 19.6 100 63.1 36.9
MSA5 status ( p  -0 .2 1 2 )
M S A ...................................................................................................................... 90.5 100 76.5 23.5
N o n -M S A ............................................................................................................. 9.5 100 62.0 38.0
Patient age ( p  -0 .1 3 6 )
15-24  years .......................................................................................................... 15.6 100 72.1 27.9
25 -4 4  years .......................................................................................................... 47.1 100 78.1 21.9
4 5 -6 4  years .......................................................................................................... 37.4 100 72.6 27.4
Patient race ( p  -  0.137)
W h ite ...................................................................................................................... 80.1 100 76.5 23.5
B la c k ...................................................................................................................... 15.5 100 70.9 29.1
O th e r ...................................................................................................................... 4.5 100 64.1 35.9
Primary payment source ( p  -  0.064)
Private in s u ra n c e .............................................................................................. 81.2 100 77.2 22.8
Medicare6 .......................................................................................................... 1.9 100 50.0 50.0
M e d ica id o rS C H IP 7 ......................................................................................... 6.9 100 65.3 34.7
All other sources................................................................................................. 10.0 100 69.1 30.9
HPV8 DNA test ordered or provided (p  -  0.405)
Y e s ......................................................................................................................... 9.4 100 80.7 *19.3
N o............................................................................................................................ 90.6 100 74.5 25.5
Preventive care reason fo r visit ( p  -  0.517)
Y e s ......................................................................................................................... 80.2 100 75.8 24.2
No or unknow n.................................................................................................... 19.8 100 72.4 27.6
* F igure does not meet standards of reliability or precision.
1p  va lues refelct ch i-square test of association between type of test and characteristic. 
2Excludes 10.4% of cytology tests with type unspecified.
3LBC is liquid-based cytology.
4Includes imputed practice s ize fo r 0.1%  of visits.
5MSA is metropolitan statistical area.
6Includes patients dually e lig ible fo r Medicare and Medicaid.
7SCHIP is State C hildren ’s Health Insurance Program.
8HPV is human papillomavirus.
S O U R C E :  C D C / N C H S ,  N a t i o n a l  A m b u l a t o r y  M e d i c a l  C a r e  S u r v e y ,  2 0 0 6 - 2 0 0 7 .
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Table 2. Adjusted odds ratio for liquid-based cytology test, and 95% confidence interval among visits made to primary care physicians 
with known type of cytology test, for females aged 15-64 who had a Pap test, by selected characteristics: United States, 2006-2007
Selected characteristic
Adjusted odds ratio 
fo r LBC1
95%  confidence 
interval
S o lo ....................................
Practice size2
..................  Reference
3 -5  phys ic ians.................. ..................  0.43 0.17-1.10
6 -1 0  p h ys ic ia n s ............... ..................  0.40 0.15-1.08




General or fam ily practice ..................  0.74 0.33-1.70
O ther p r im a r y .................. ..................  0.54 0.25-1.17
Physician or group ..........
Practice ownership
..................  Reference
Health maintenance o rg a n iz a t io n ......................................................... ..................  0.26 0.04-1.75
Community health center ..................  0.61 0.26-1.39
O ther ow nersh ip ............... ..................  0.88 0.32-2.42
N orthe a s t............................
Geographic region
..................  Reference
M id w e s t.............................. ..................  0.91 0.24-3.49
S o u th ................................. ..................  1.11 0.40-3.11
W e s t .................................... ..................  0.53 0.18-1.56
M S A ....................................
MSA3 status
..................  2.15 0.69-6.76
N o n -M S A ........................... ..................  Reference
15-24  y e a r s .....................
Patient age
..................  Reference
25 -4 4  years ...................... ..................  1.30 0.83-2.03
4 5 -6 4  years ...................... ..................  1.06 0.66-1.70
W h ite ....................................
Patient race
..................  Reference
B lack .................................... ..................  0.70 0.39-1.26
O the r.................................... ..................  0.83 0.46-1.52
Private in s u ra n c e ............
Primary payment source
..................  Reference
M edicare4 ........................... ...............  0.25 0.10-0.60
Medicaid or SCHIP5 . . . . ...............  0.64 0.32-1.25
All other sources................ ..................  0.81 0.45-1.44
HPV6
Y e s .......................................
DNA test ordered or provided
..................  1.23 0.48-3.15
N o ....................................... ..................  Reference
Preventive care reason for visit 
Y e s ................................................................................................................... ..................  1.20 0.68-2.11
No or unknown.................. ..................  Reference
. . . Category not applicable.
1LBC is liquid-based cytology. Based on 1,483 visits with known type of cytology test. 
2Includes imputed practice s ize fo r 0.1%  of v isits.
3MSA is metropolitan statistical area.
4Includes patients dually e lig ible fo r Medicare and Medicaid.
5SCHIP is State C hildren ’s Health Insurance Program.
6HPV is human papillom avirus.
S O U R C E :  C D C / N C H S ,  N a t i o n a l  A m b u l a t o r y  M e d i c a l  C a r e  S u r v e y ,  2 0 0 6 - 2 0 0 7 .
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